Skin reactivity to histamine and expression of histamine receptors mRNA in lymphocytes of healthy subjects and non-small-cell lung cancer patients before and after surgery

Zak-Nejmark, T; Jankowska, Renata; Passowicz−Muszyńska, Ewa; Małolepszy, J; Marciniak, Marek; Jonkisz, Anna; Kraus-Filarska, M

doi:10.1016/j.lungcan.2004.01.005

Cited by 1 publication

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assessment of immune cells and cytokines is necessary to evaluate the immune response in patients (Table 3) [131314182022252729303134353942434447505152535460636772798081858687889091939597103116117118119120121122123124125126127128129130131132]. The innate immune response is rapid and does not require prior exposure to an antigen.…”

Section: Approaches For Evaluating Inflammatory Parametersmentioning

confidence: 99%

Biomarkers for Evaluating the Inflammation Status in Patients with Cancer

Güner

Kim

2019

J Gastric Cancer

View full text Add to dashboard Cite

Inflammation can be a causative factor for carcinogenesis or can result from a consequence of cancer progression. Moreover, cancer therapeutic interventions can also induce an inflammatory response. Various inflammatory parameters are used to assess the inflammatory status during cancer treatment. It is important to select the most optimal biomarker among these parameters. Additionally, suitable biomarkers must be examined if there are no known parameters. We briefly reviewed the published literature for the use of inflammatory parameters in the treatment of patients with cancer. Most studies on inflammation evaluated the correlation between host characteristics, effect of interventions, and clinical outcomes. Additionally, the levels of C-reactive protein, albumin, lymphocytes, and platelets were the most commonly used laboratory parameters, either independently or in combination with other laboratory parameters and clinical characteristics. Furthermore, the immune parameters are classically examined using flow cytometry, immunohistochemical staining, and enzymelinked immunosorbent assay techniques. However, gene expression profiling can aid in assessing the overall peri-interventional immune status. The checklists of guidelines, such as STAndards for Reporting of Diagnostic accuracy and REporting recommendations for tumor MARKer prognostic studies should be considered when designing studies to investigate the inflammatory parameters. Finally, the data should be interpreted after adjusting for clinically important variables, such as age and cancer stage.

show abstract